The case for & against
Bull & Bear analysis
Inogen Inc. (NASDAQ: INGN) is a leading medical technology company specializing in portable oxygen concentrators (POCs) and related respiratory therapy solutions. With a strong focus on innovation, Inogen is transforming its operations from being solely reliant on POCs to a broader respiratory care provider including sleep therapy and digital health solutions. The company aims to leverage its strengths in both direct-to-consumer (DTC) and business-to-business (B2B) channels while expanding its presence in emerging markets like Brazil and China, capitalizing on the growing demand for non-traditional oxygen therapy solutions amidst a transition in consumer preferences.
Bull says
- ↑Q1 2026 revenue up 5.5% YoY to $82.3M, driven by product sales
- ↑Adjusted EBITDA turned positive at $36K vs. –$7.6M prior year
- ↑Ended Q1 2026 with $122.5M cash and zero debt, funding growth
- ↑Aurora and Voxy launches posting high reorder rates boosting B2B
- ↑$30M share buyback underscores management’s confidence
- ↑Analysts raised earnings forecasts, signaling optimism on upside
Bear says
- ↓Direct-to-consumer sales fell 21.1% YoY to $15.8M, weakening core growth
- ↓Gross margin under pressure as lower-margin B2B mix grows despite 44.2% overall
- ↓Operating expenses set to rise in H2, challenging profitability recovery
- ↓High short interest reflects investor skepticism on execution
- ↓Weak profitability metrics highlight doubts over sustainable returns
- ↓Competition from ResMed, Philips and new entrants may erode share
Investment themes with INGN
Clinical instruments and devices powering patient care
Companies paying above-average dividends
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- We feel like even because of the timing that Kevin mentioned, because of the limited freight that we have, you know, that we'd be able to, we would expect to be able to offset it at current levels for 2026.
- we're managing OPEX to kind of make sure that we end up in a position of growing EBITDA over the course of the year.
- the gross margin expansion, which I think is really critical for us as we think about some of the mixed pressures we see in the market.
Bear points
- you know, just looking at your adjusted net loss, if I'm remembering correctly, when I glance at the press release, but a lot of companies are poor tonight, but I think it was flat to maybe even down from, from last year on an adjusted basis. Um, I know EBITDA was, was not the same, but, you know, can you maybe just talk about what's, what's happening there and what, you know, why weren't getting more kind of leverage, I guess, or, or cost savings from a, you know, OPEX perspective or whatever.
- you know, just looking at your adjusted net loss, if I'm remembering correctly, when I glance at the press release, but a lot of companies are poor tonight, but I think it was flat to maybe even down from, from last year on an adjusted basis. Um, I know EBITDA was, was not the same, but, you know, can you maybe just talk about what's, what's happening there and what, you know, why weren't getting more kind of leverage, I guess, or, or cost savings from a, you know, OPEX perspective or whatever.
- you know, just looking at your adjusted net loss, if I'm remembering correctly, when I glance at the press release, but a lot of companies are poor tonight, but I think it was flat to maybe even down from, from last year on an adjusted basis. Um, I know EBITDA was, was not the same, but, you know, can you maybe just talk about what's, what's happening there and what, you know, why weren't getting more kind of leverage, I guess, or, or cost savings from a, you know, OPEX perspective or whatever.